NEW YORK, May 23, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Organon & Co. (“Organon” or the “Company”) (NYSE: OGN) between October 31, 2024, to April 30, 2025, both dates inclusive. You are hereby notified that the class action lawsuit Joseph Hauser v.

NEW YORK, NY / ACCESS Newswire / May 23, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders.

NEW YORK, NY / ACCESS Newswire / May 23, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own TaskUs, Inc. ("TASK" or the "Company") (NASDAQ:TASK) stock purchased prior to May 9, 2025. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the proposed purchase of the company's outstanding Class A shares by an affiliate of Blackstone, the TaskUs Co-Founder and Chief Executive Officer Bryce Maddock, and TaskUs Co-Founder and President Jaspar Weir.

NEW YORK CITY, NY / ACCESS Newswire / May 23, 2025 / WHY: New York, N.Y., May 23, 2025.

NEW YORK, NY / ACCESS Newswire / May 23, 2025 / If you suffered a loss on your Treace Medical Concepts, Inc. (NASDAQ:TMCI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/treace-medical-concepts-inc-lawsuit-submission-form-2?prid=150013&wire=1&utm_campaign=11 or contact Joseph E. Levi, Esq.

Victoria's Secret & Co. Q1 results are expected to be unremarkable, with sales and EPS in line with management and analyst guidance. The main VSCO focus is the hostile takeover attempt by BBRC, countered by a poison pill defense to protect existing shareholders from losing control. BBRC's 13% stake and potential to reach 49.99% create uncertainty, with the board aiming to prevent a single investor's dominance.

Strong Q1 2025 results reinforce my positive investment thesis for the company. Valuation remains attractive compared to peers, supporting a favorable risk/reward profile. Key risks include potential market volatility and execution challenges in upcoming quarters.

Salesforce Inc (NYSE:CRM, ETR:FOO) is set to deliver first-quarter revenue in line with guidance, but investors should expect limited upside on remaining performance obligations and conservative comments from management, according to analysts at Jefferies. The company will hand down its fiscal Q1 earnings for the three months ending in April on Wednesday, May 28, after markets close.

Known Tesla bull Dan Ives sees a ‘golden age' for Tesla based on AI and AVs, but that optimistic view faced a colder reality of trade-war fears.

Business development companies, or BDCs, are inherently risk-on assets that operate in a volatile segment (private credit). In most cases they do not go well together with retirement income portfolios. Yet, there are some rare exceptions.

Advance Auto Parts, Inc. AAP posted better-than-expected first-quarter financial results on Thursday.

Mike Shorr with @ProsperTradingAcademy focuses on three companies with expansive reach in ecommerce and digital advertising. He notes Maplebear (CART) brushing up against a key resistance level, Roku Inc.'s (ROKU) vulnerability of "outperforming to the downside," and his bullish expectations on Amazon (AMZN).

NEW YORK, NY / ACCESS Newswire / May 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of UroGen Pharma Ltd. ("UroGen Pharma Ltd.

NEW YORK, NY / ACCESS Newswire / May 23, 2025 / If you suffered a loss on your West Pharmaceutical Services, Inc. (NYSE:WST) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/west-pharmaceutical-services-inc-lawsuit-submission-form?prid=150008&wire=1&utm_campaign=12 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / May 23, 2025 / If you suffered a loss on your Napco Security Technologies, Inc. (NASDAQ:NSSC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/napco-security-technologies-inc-lawsuit-submission-form-2?prid=150009&wire=1&utm_campaign=13 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / May 23, 2025 / If you suffered a loss on your UnitedHealth Group Incorporated (NYSE:UNH) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/unitedhealth-group-incorporated-lawsuit-submission-form?prid=150011&wire=1&utm_campaign=27 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / May 23, 2025 / If you suffered a loss on your Compass Group Diversified Holdings, LLC (NYSE:CODI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/compass-diversified-lawsuit-submission-form?prid=150012&wire=1&utm_campaign=15 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / May 23, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=150007&wire=1&utm_campaign=30 or contact Joseph E. Levi, Esq.

Baidu, Inc. reported strong Q1 results, but soft advertising revenue weighed on stock performance. Investors are likely concerned that economic headwinds in China will continue to impact near-term earnings visibility. AI-related endeavors, accomplishments and BIDU spending remain strong, which is both an opportunity and a further burden on earnings.

While Keysight is well-positioned for secular growth (6G, AI), the current stock price may already reflect much of this future optimism, limiting the immediate upside. Keysight's stock (around $161.74) appears to have a high forward P/E of 24x, potentially outpacing its "gradual recovery" forecast. The pending Spirent LSA acquisition (closing Q3'25) offers software growth potential but also brings integration complexities and execution risks to watch closely.